CDMOs announced expansions, exhibitors showcased automated equipment, and supply chain strategy discussions were a focus at CPHI Milan 2026.
News|Articles|July 2, 2003
- Pharmaceutical Technology-07-02-2003
- Volume 27
- Issue 7
Capacity Worries Fade for Biomanufacturing
Author(s)Jim Miller
The DSM investment puts biomanufacturing capacity in the spotlight. Contract biomanufacturers are adding new capacity and sponsors are marketing their excess capacity.
Advertisement
Articles in this issue
over 23 years ago
July 2003over 23 years ago
The Push for Generics Challenges Manufacturersover 23 years ago
Emerging Research Opportunities in Oral Inhalation Technologyover 23 years ago
Preventing Metal ContaminationAdvertisement
Related to this article
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
Who Answers for Your Data? Building a Life Sciences Data Mesh
4
Improving Oral Peptide Delivery Through Structural Modifications
5